In Silico vs. In vivo Human Intestinal Permeability

Abstract

The aim of this research is to calculate human intestinal permeability in silico and correlate results with those measured in vivo. Optimized human intestinal permeability values were calculated for 16 drugs by de-convolution of human plasma profiles using Parameter Estimation module of SimCYP program V13. Results showed high in silico-in vivo correlation coefficient of 0.89 for drugs with high/low permeability values. In silico permeability, if properly optimized, can be used as surrogate for in vivo permeability for BCS class I drugs and hence is suggested that such methodology could be employed as a support for waiver of in vivo studies.

• References

• 1 Wu C-Y, Benet LZ. Pharmaceutical Research 2005; 22: 11-23
• 2 Idkaidek N, Arafat T. Molecular Pharmaceutics 2012; 9: 2358-2363
• 3 Amidon GL, Lennernas H, Shah VP et al. Pharmaceutical Research 1995; 12: 413-420
• 4 Kasim NA, Whitehouse M, Ramachandran C et al. Molecular Pharmaceutics 2003; 1: 85-96
• 5 Jamei M, Turner D, Yang J et al. AAPS J 2009; 11: 225-237
• 6 Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000. Division of Drug Information, CDER, US FDA, 5600 Fishers Lane Rockville, MD 20857, USA
• 7 Guideline on the investigation of bioequivalence, 2010 CPMP/QWP/EWP/1401/98 Rev. 1